Login to Your Account

Rockwell's Iron Therapy SFP Proves Its 'Metal' in Phase III

By Randy Osborne
Staff Writer

Thursday, July 11, 2013
After taking a stock hit on the ominous promise of a conference call the next morning, Rockwell Medical Inc. turned investor worries around with news that the firm had encouraging top-line data to offer from the Phase III study known as CRUISE-1, testing SFP, an iron-delivery drug for chronic kidney disease patients on dialysis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription